BiotechTube

Risk of low dose aspirin discontinuation

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cardiovascular Prevention

Conditions

Cardiovascular Prevention

Trial Timeline

Sep 1, 2012 → Jun 1, 2013

NCT ID
NCT01888575

About Risk of low dose aspirin discontinuation

Risk of low dose aspirin discontinuation is a pre-clinical stage product being developed by AstraZeneca for Cardiovascular Prevention. The current trial status is completed. This product is registered under clinical trial identifier NCT01888575. Target conditions include Cardiovascular Prevention.

What happened to similar drugs?

9 of 20 similar drugs in Cardiovascular Prevention were approved

Approved (9) Terminated (2) Active (9)
🔄polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
🔄Dulaglutide + PlaceboEli LillyPhase 3
🔄raloxifene + placeboEli LillyPhase 3
🔄Orforglipron + PlaceboEli LillyPhase 3
✅Rosuvamibe + MonorovaYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01888575Pre-clinicalCompleted

Competing Products

20 competing products in Cardiovascular Prevention

See all competitors
ProductCompanyStageHype Score
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
Dulaglutide + PlaceboEli LillyPhase 3
40
raloxifene + placeboEli LillyPhase 3
40
EvacetrapibEli LillyPhase 1
29
Orforglipron + PlaceboEli LillyPhase 3
47
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
35
Rosuvamibe + MonorovaYuhanApproved
39
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
43
Rosuvamibe + MonorovaYuhanApproved
43
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
43
LexiscanAstellas PharmaPhase 2
35
mirabegron + tamsulosinAstellas PharmaPhase 1
29
TRC150094Torrent PharmaceuticalsPhase 1/2
32
Lorcaserin hydrochloride + PlaceboEisaiApproved
43
Lepodisiran Sodium + PlaceboEli LillyPhase 3
44
Retatrutide + PlaceboEli LillyPhase 3
44
Empagliflozin + PlacebosEli LillyApproved
43
Evacetrapib + PlaceboEli LillyPhase 3
32
Placebo + AZD0780AstraZenecaPhase 2
35
Midazolam + AZD5718AstraZenecaPhase 1
29